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Abstract
Progression to androgen-independent status is the main cause of death in patients with
metastatic prostate cancer. Prostate-specific membrane antigen (PSMA) is anchored in
the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate
epithelial cells and strongly upregulated in prostate cancer. Therefore, it is an appro‐
priate target for diagnosis and therapy of prostate cancer and its metastases. There is
growing knowledge about promising response and low toxicity profile of radioligand
therapy of metastatic castration-resistant prostate cancer using Lutetium-177-labeled
PSMA ligands. For patients with only bone metastases, there are different radionu‐
clides which have been used for decades. In this chapter, different methods of targeted
radionuclide therapy of metastatic prostate cancer are described.
Keywords: PSMA, prostate cancer, radioligand therapy, metastatic disease, PSA, bone
metastasis, radionuclide therapy
1. Introduction
Almost all patients with metastatic prostate cancer (PC) will initially respond to well-estab‐
lished and innovative anti-androgen treatments including the two recently approved hormone
therapy agents,  enzalutamide and abiraterone [1,  2],  which significantly improve overall
survival. However, progression to androgen-independent status is the main cause of death in
these patients [3]. Most deaths related to PC are due to metastatic disease, which results from
any combination of blood, lymphatic, or local spread. Targeted radionuclide therapy is an
attractive and quickly developing therapy option for many different cancers, such as lym‐
phoma,  melanoma,  and neuroendocrine  tumors  [4–7].  Radionuclide  therapies  should be
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targeted, because this procedure always involves the administration of unsealed sources of
radioactivity.
Most therapeutic tracers utilize β-particle emissions due to the ability of these particles to
penetrate tissues. The deposition of energy in tissue by β-emitters results in cellular damage.
Among the β-emitters, there are several choices regarding the energy of the β-emission. Lower
energy β-particles can travel a few cell diameters, or at most in the submillimeter range. Higher
energy β-particles, such as those emitted by Yttrium-90 (90Y) or Lutetium-177 (177Lu), have
excellent tissue penetration with a range beyond the source of several millimeters [8, 9]. The
only routinely used α-emitter for the treatment of metastatic disease is Radium-223 (223Ra),
which has been approved for the treatment of bone metastases in patients with prostate cancer
and symptomatic disease with no known visceral metastases [10]. The physical half-life of
therapeutic radionuclide is an important consideration and an underlying principle for
therapy planning [11].
2. PSMA as a target
Prostate-specific membrane antigen (PSMA), also known as folate hydrolase I or glutamate
carboxypeptidase II, is a type II transmembrane protein anchored in the cell membrane of
prostate epithelial cells [12]. Several biological characteristics make PSMA an outstanding
target for drug development. PSMA is highly expressed on prostate epithelial cells and
strongly upregulated in PC. PSMA expression levels are directly correlated to androgen
independence, metastasis, and PC progression [13]; thus, PSMA is an attractive target for the
diagnosis and therapy of metastasized PC. Its target specificity is maintained after radiolab‐
eling with 68Ga [12, 14].
A commonly used radionuclide is 68Ga-PSMA-11, which has been successfully used for the
imaging of PC with high sensitivity and specificity, even in patients with very low prostate-
specific antigen (PSA) levels (<2 ng/ml) [15]. Direct comparison studies support the superiority
of 68Ga-PSMA-11 in lymph node assessment over CT 3D volumetric-based lymph node
assessments [16] and in overall disease assessment compared to 18F-methylcholine, especially
in patients with low PSA levels [17]. These positive results will lead to or have already led to
a paradigm shift in the use of imaging in primary staging of PC. In a recent study by Hijazi et
al., the diagnostic accuracy of 68Ga-PSMA-11 in the preoperative assessment of nodal meta‐
stases was very high for macrometastases and even micrometastases in lymph nodes. Corre‐
lating imaging and tissue specimens of 213 removed nodes provided 94% sensitivity, 99%
specificity, 89% positive predictive value, and 99.5% negative predictive value [18].
3. PSMA radioimmunotherapy
After rather unsuccessful therapy with the 90Y-CYT-356 monoclonal antibody (mAb) recog‐
nizing the intracellular domain of PSMA [19], Phase I and II clinical trials utilizing the PSMA
mAb J591, radiolabeled with 177Lu or 90Y, have shown promising results [20–23].
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J591 is an anti-PSMA mAb that binds with 1 nM affinity to the extracellular domain of PSMA
[24, 25]. Milowsky et al. [26] treated 29 patients in the 90Y-J591 Phase I trial; patients received
therapeutic doses of 185, 370, 555, 647.5, and 740 MBq/m2 90Y-J591. Dose-limiting toxicity was
seen at 740 MBq/m2, with two patients experiencing thrombocytopenia with nonlife-threaten‐
ing bleeding episodes requiring platelet transfusions. The 647.5 MBq/m2 dose was determined
to be the maximum tolerated dose (MDT).
Bander et al. [21] treated 35 patients with progressing androgen-independent PC with 177Lu-
J591, and 16 of these patients received up to three doses. Myelosuppression was dose-limiting
at 2775 MBq/m2, and the 2590 MBq/m2 dose was determined to be the single-dose MTD. Repeat
dosing at 1665–2220 MBq/m2 was associated with dose-limiting myelosuppression [21]. The
authors reported good targeting of all known sites of bone and soft tissue metastases in all
patients. They found no clear relationship between a history of prior chemotherapy treatment
and the degree of toxicity. Biological activity was seen with four patients experiencing ≥50%
declines in PSA levels lasting from 3 to 8 months. An additional 16 patients (46%) experienced
PSA stabilization for a median of 60 days [21]. Tagawa et al. presented the results of a Phase
II study of radionuclide therapy with the 177Lu-PSMA mAb J591 [20], which was based on two
published Phase I studies investigating this agent [21, 26]. In this study [20], 47 hormone-
refractory patients (55.3% also had received chemotherapy) were treated with 177Lu-J591. They
compared two different doses (2405 vs. 2590 MBq/m2). About 11% of patients experienced a
≥50% decline in PSA, 36.2% experienced a ≥30% decline in PSA, and 59.6% experienced any
PSA decline following a single therapy. All experienced reversible hematological toxicity, with
Grade 4 thrombocytopenia occurring in 46.8% without significant hemorrhage. Grade 4
neutropenia happened in a total of 25.5% of patients, with one episode of febrile neutropenia.
The 2590 MBq/m2 dose resulted in not only 30% more of PSA decline (46.9 vs. 13.3%, P = 0.048)
and longer survival (21.8 vs. 11.9 months, P = 0.03), but also more Grade 4 hematological
toxicity and platelet transfusions. mAb are large molecules, and therefore show poor perme‐
ability in solid tumors and slow clearance from the circulation. This combination leads to
suboptimal targeting and an increased absorbed dose in the bone marrow, narrowing the
therapeutic window [27]. Thus, radionuclide treatment with 90Y-J591 and 177Lu-J591 is limited
by myelosuppression and nonhematological toxicity, with a maximum tolerated activity per
cycle of 650 and 2450 MBq/m2, respectively.
4. PSMA radioligand therapy with a small-molecule inhibitor
The synthesis and design of a series of small-molecule inhibitors of PSMA have been described
by Maresca et al. [28]. On the basis of the work of this group, Hillier et al. [29] performed a
preclinical evaluation of two radiopharmaceuticals, 123I-MIP-1072 and 123I-MIP-1095, which
were designed to target PSMA in PC cells and tissue. In a recent published study from the
Heidelberg group, Zechmann et al. showed the utility of 131I-MIP-1095 PSMA [27]. Therapy
with 131I-MIP-1095 PSMA was performed in 25 patients. The patients received a single
therapeutic dose of 131I-MIP-1095 (mean activity 4.8 GBq, range 2.0–7.2 GBq). Erythrocyte
counts fell below the normal range at the nadir in 21 patients, with 17 patients having lower
values prior to therapy. In 14 patients, white blood cell counts fell below the normal range after
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therapy (one with Grade 3 toxicity). However, five of these 14 patients had levels below normal,
prior to therapy (four Grade 1, one Grade 2); 11 patients had a reduction in platelet count below
normal after therapy (two Grade 3), and one had a value below normal (Grade 2), prior to
therapy. The changes in hematological parameters were not related to the activity adminis‐
tered. The onset of the myelosuppression occurred within 6 weeks after treatment with a quite
variable time to recovery, in some cases requiring up to 3–6 months for recovery. White blood
cells typically recovered within several weeks, whereas platelets required several months to
recover [12, 27]. In contrast to mAb, the low-molecular-weight compounds, with higher
permeability into solid tumors, offered a significant advantage in achieving higher uptake per
gram of tumor tissue and a higher percentage of specific binding. Moreover, small molecules
displayed more rapid tissue distribution and faster blood clearance compared with intact
immunoglobulins. These properties often lead to a higher target to nontarget tissue ratio,
which is important for successful application of therapeutic absorbed doses [27].
131I has a long half-life of 8.02 days and has a β-particle range in soft tissue of just 0.8 mm. Due
to its γ-emitting properties and long half-life, 131I is less attractive from a radiation safety point
of view. 90Y has a half-life of 64 h, but only undergoes high-energy β-emission, resulting in a
long mean β-particle range of 3.6 mm and a maximum range of 10 mm in soft tissue. Due to
its long β-particle range, collateral damage to surrounding tissues is quite high [30].
Recently, a novel theranostic drug, 177Lu-PSMA 617, which is a DOTA-derivative of the Glu–
urea–Lys motif, has been developed for the treatment of patients with metastatic PC [29, 31].
177Lu has a half-life of 6.7 days and undergoes low-energy β-particle emission with a mean
range of 1 mm and a maximum range of 2–4 mm in soft tissue. So, the practical issues sur‐
rounding radiation safety with 131I and the limited collateral damage to surrounding tissues
compared to 90Y make 177Lu-labeled radionuclide treatment the most attractive option from a
physics point of view. Ahmadzadehfar et al. [32] reported on the first 10 consecutive patients
who were treated with 177Lu-PSMA-617 in their department (University Hospital Bonn and
Muenster, Germany). They showed that 8 weeks after the therapy in these 10 patients, seven
patients showed a PSA decline, of whom six experienced a more than 30% and five a more
than 50% decline. Three patients showed progressive disease according to the PSA increase.
No patients experienced any side effects immediately after injection of 177Lu-PSMA 617 [32].
Relevant hematotoxicity (Grade 3 or 4) occurred 7 weeks after the administration in just one
patient. These encouraging results showed again the efficacy of radionuclide therapy in
patients who have no other approved therapeutic option. A later study by the group from
Bonn showed the efficacy and safety of 177Lu-PSMA 617 therapy in patients who had under‐
gone two cycles of therapy [8]. In this study, 46 cycles of 177Lu-PSMA 617 were performed in
24 consecutive hormone and/or chemorefractory patients. Twenty-two patients received two
cycles of therapy. Twenty-two patients had a history of or were on therapy with enzalutamide
and/or abiraterone. Twelve patients had received 223Ra (1–6 cycles; median 5 cycles). All
patients had multiple bone metastases, and the majority of them also had lymph node
metastases. The mean and median PSA levels prior to therapy were 628.3 and 522 ng/ml,
respectively (range: 17.1–2360 ng/ml). It was found that 8 weeks after the first cycle of 177Lu-
PSMA therapy, 19/24 patients (79.1%) experienced a PSA decline, out of whom 13 experienced
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a decline of more than 30% and 10 more than 50% (41.6%). Five patients showed progressive
disease according to an increase in PSA. Two months after the second cycle in 22 patients who
underwent two cycles of 177Lu-PSMA therapy, 15/22 patients (68.2%) experienced a PSA
decline in comparison to the baseline PSA value, of whom 15 experienced a decline of more
than 30%, and 13 (60%) of more than 50%. Seven patients showed progressive disease accord‐
ing to an increase in PSA or disease progression. Again, in this study, the patients received
radioligand therapy as the last therapeutic option [8]. Interestingly, although a majority of
prostate cancer patients at such an advanced stage of disease with massive bone marrow
infiltration suffer from anemia, relevant hematotoxicity (Grade 3) occurred during the
observation period (within 2 months after the last cycle) in just two patients. Apart from some
Grade 1 or 2 hematotoxicity, the majority of patients did not show any hematotoxicity during
the observation period. Some patients who needed blood transfusions prior to the first cycle
needed fewer transfusions after radioligand therapy with 177Lu-PSMA 617 because of the
regression of bone marrow involvement [33]. The Nordrhein–Westfalen study group recently
published the results of single-dose administration of 177Lu-PSMA 617 in 74 patients. They
showed a PSA decline in 47 patients (64%); of these, 23 (31%) had a PSA decline >50%; 35 (47%)
had stable disease with a PSA decline from <50% to an increase of <25%; and 17 (23%) showed
progressive disease with a PSA increase >25%. Response and tolerability of a single dose of
177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter
retrospective analysis.
Figure 1. (A) 68Ga-PSMA PET scan of a 66-year-old hormone- and chemorefractory patient with multiple bone and
lymph node metastases (pink arrows), with a history of chemotherapy, abiraterone, and 223Ra therapies. (B) The follow-
up PET scan prior to the second cycle shows a partial response with regression of the metastases and PSA decline. (C)
The PET scan, 2 months after the third cycle of Lu-PSMA therapy, which shows a very good response with further
decline of PSA.
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Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadza‐
dehfar H. J Nucl Med. 2016 Apr 7. pii: jnumed.116.173757. [Epub ahead of print]
Further research into the efficacy of this therapy is needed. Rahbar et al. showed for the first
time the overall survival benefit of RLT in comparison to a historical collective. They showed
that the estimated median survival was 29.4 weeks, significantly longer than the survival in
the historical control group at 19.7 weeks [hazard ratio: 0.44 (95% confidence interval: 0.20–
0.95); P = 0.031] [34] (Figure 1).
5. Treatment of bone metastases with radionuclides
Bone metastases, a major cause of morbidity and mortality in patients with castration-resistant
prostate cancer, are associated with pain, pathological fractures, spinal cord compression, and
decreased survival [35]. The major mechanism of pain from small metastases appears to be the
stimulation of nerve endings in the endosteum by a variety of chemical mediators. Larger bone
metastases produce stretching of the periosteum, which leads to pain [36]. The incidence of
bone metastases in patients with prostate cancer, according to autopsy studies, is 65–85% [37].
Bone pain palliation with radionuclides has a very long history of using different β-emitters
such as phosphorus-32 (32P) [38], strontium-89 (89Sr) [38], rhenium-186-hydroxyethylidene
diphosphonate (186Re-HEDP) [39], 188Re-HEDP, samarium-153-EDTMP (153Sm-EDTMP) [39],
and recently, lutetium-177-EDTMP (177Lu-EDTMP) [40] and 177Lu-BPAMD [41]. The only
approved α-emitter is radium-223 (223Ra) [42].
Calcium analogues Attached to phosphate
Strontium-89 Phosphorus-32
Radium-223 Samarium-153-EDTMP
Rhenium-186-HEDP
Rhenium-188-HEDP
Lutetium-177-EDTMP
Lutetium-177-BPAMD
Table 1. Different radionuclides for bone palliation.
Bone-seeking radionuclides are classified into two groups: calcium analogues and radionu‐
clides attached to phosphate (Table 1). Different radionuclides have different physical char‐
acteristics, which are shown in Table 2.
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Emission
type
t½
(days)
Maximum energy
(MeV)
Max tissue
penetration range (mm)
Phosphorus-32 β 14.3 1.7 8.5
Strontium-89 β 50.5 1.46 7
Samarium-153 β and γ 1.9 0.81 4
Rhenium-186 β and γ 3.7 1.07 5
Rhenium-188 β and γ 0.7 2.1 10
Lutetium-177 β and γ 6.7 0.498 1.8
Radium-223 αand γ 11.4 27.78 0.1
All, but Radium-223, are β-emitters.
Table 2. Summary of the main physical properties of different radionuclides in clinical use for pain palliation.
5.1. 32Phosphorus
32P decays by 1.7 MeV (Emax) β-emission and has a physical half-life of 14.3 days, with a
maximum tissue penetration of 8.5 mm (Table 2) [43]. During treatment with 32P, pain relief
was reported by 50–87% of patients treated with 200–800 MBq of 32P administered daily in 20–
80 MBq fractions after androgen priming. Pain reduction occurred within 5–14 days, with a
mean response duration of 2–4 months [38, 44, 45] (Table 3). The main disadvantage of 32P
therapy is dose-limiting myelosuppression with reversible pancytopenia maximal at 5–6
weeks after administration [46].
Radiopharmaceutical activity Typical response
time 
Typical response
duration 
Retreatment interval
Phosphorus-32 444 MBq (fractionated) 14 days 10 weeks <3 months
Strontium-89 chloride 150–200 MBq 14–28 days 12–26 weeks <3 months
Samarium-153-EDTMP 37 MBq/kg 2–7 days 8 weeks <2 months
Rhenium-186-HEDP 1.3 GBq 2–7 days 8–10 weeks <2 months
Rhenium-188-HEDP 1.3–4.4 GBq 2–7 days 8 weeks 2 months
Refs. [93–95].
Table 3. Bone-seeking radionuclides.
5.2. 89Strontium
89SrCl2 is an element that behaves like calcium and localizes in bone, primarily in areas of
osteoblastic activity. It decays by 1.4 MeV (Emax) β-emission, with a long physical half-life of
50.5 days. The maximum penetration range in tissue is about 7 mm. Excretion is predominantly
renal, dictated by the skeletal tumor burden and glomerular filtration rate [47, 48].
The biological half-life in normal bone is around 14 days, compared with more than 50 days
in osteoblastic metastases. The first studies using 89Sr demonstrated efficacy for pain reduction
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as high as 80%. Complete response rates vary widely among studies and have been reported
in 8–77% of cases. The overall response rate varied from 33 to 82% [49–54]. It was the first
radiopharmaceutical to be approved for systemic radionuclide therapy in the palliation of
painful bone metastases. The standard recommended dose of 89Sr is 150–200 MBq (Table 3). It
was shown to be as effective as both local field and hemibody external-beam radiotherapy in
relieving existing bone pain, but delayed the development of new pain at preexisting, clinically
silent sites [45, 55].
Toxicity is limited with the common development of thrombocytopenia, with the nadir
between the 4th and 6th weeks. Recovery is typically slow over the next 6 weeks, dictated by
skeletal tumor extent and bone marrow reserve [45].
The largest study was published by Robinson et al. In this study, 622 patients were included
(466 with prostate cancer). About 15% of patients showed complete pain relief, and a partial
response was documented in 81% [56–58]. Tu et al. [59] reported improved survival using six
weekly administrations of 89SrCl2 combined with doxorubicin after induction chemotherapy,
compared with six weekly administrations of doxorubicin alone; however, the follow-up Phase
II trial of the same study group did not confirm the positive effect of this combination therapy
on overall survival [60].
A nonrandomized study using 12 weekly administrations of estramustine phosphate, vin‐
blastine, and 89SrCl2 recorded effective, durable symptom palliation, more than a 50% reduc‐
tion in PSA in 48% of treated patients, and reduced demand for subsequent palliative
radiotherapy [61]. Several patient characteristics could predict a favorable response to 89Sr. A
normal serum hemoglobin level prior to treatment is associated with a higher pain response
rate [62]. Other predictors of a poor pain response were low performance status, higher serum
PSA, more extensive osseous metastases, and a poor PSA response [63–66].
5.3. 186Rhenium-HEDP
186Re is a medium-energy β-emitter with a physical half-life of 89 h.186Re-1,1-hydroxyethylidene
diphosphonate (186Re-HEDP) is a surface bone-seeking radiopharmaceutical used for internal
radiotherapy. The maximum tolerated activity is 2960 MBq, but for routine use the recom‐
mended activity is 1285 MBq. Peak skeletal uptake occurs 3 h after intravenous administration
[67, 68]. An early study by Maxon et al. [69] using 1285 MBq of 186Re-HEDP documented overall
pain relief in 80% of patients, with a mean duration of 7 weeks in hormone refractory PC
patients (Table 3) [70]. Eighty to ninety percent of patients reported improved symptoms after
a single 186Re-HEDP administration. The response was typically rapid, occurring within 24–48
h of activity administration. Placebo-controlled, randomized studies have confirmed the
efficacy of 186Re-HEDP [70, 71].186Re-HEDP undergoes rapid urinary excretion and rapid blood
clearance (plasma half-life of 41 h) [70]. For the standard applied activity of 1285 MBq, 186Re-
HEDP provided a median radiation-absorbed dose of 26 Gy to bone metastases and 1.73 Gy
to the red bone marrow [70]. The tumor to marrow dose ratios had a high therapeutic index,
with a mean value of 34:1 [69]. Toxicity was limited to temporary myelosuppression, with
platelet and neutrophil nadirs at 4 weeks after therapy. Recovery occurred within 8 weeks and
was usually complete [72].
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5.4. 188Rhenium-HEDP
188Re has a short physical half-life of 16.8 h and a maximum β-particle energy of 2.1 MeV with
a 15% γ-component of 155 keV. The maximum β-range in tissue is approximately 10 mm [73].
Blood clearance is rapid after injection, with 41% renal clearance within 8 h of administration.
Absorbed doses for bone metastases are in the range of 3.83 ± 2 mGy/MBq, in comparison with
0.61 ± 0.2 mGy/MBq for bone marrow and 0.07 ± 0.02 mGy/MBq for the whole body. The mean
effective whole-body half-life is 11.6 ± 2.1 h compared with 15.9 ± 3.5 h in bone metastases [45].
188 Re is of special interest in clinical applications because of its excellent availability and cost-
effectiveness, as it is the product of a 188W (188W/188Re) generator [74].
The short physical half-life and high dose rate are predicted to lead to a rapid symptom
response. Fractionated therapy has been shown to prolong response duration and progression-
free survival (PFS). Palmedo et al. [73] randomly assigned 64 patients to two different groups
for radionuclide therapy with 188Re-HEDP; patients in group A received a single injection,
while patients in group B received two injections with an 8-week interval. In both groups,
toxicity was low, with moderate thrombopenia and leukopenia. Repeated 188Re-HEDP
therapies (group B) were more effective for pain palliation compared to group A, with a
response rate and time of response of 92% and 5.66 months, respectively (P = 0.006 and P =
0.001). In group B, 11/28 patients (39%) had a PSA decline of more than 50% for at least 8 weeks,
compared with 2/30 patients (7%) in group A. The median times to progression in group A
and group B were 2.3 months (0–12.2 months) and 7.0 months (0–24.1 months), respectively
(P = 0.0013), and the median overall survival times were 7.0 months (range, 1.3–36.7 months)
and 12.7 months (range, 4.1–32.2 months), respectively (P = 0.043) [74].
Liepe et al. [75] reported moderate transient bone marrow toxicity with a decrease in the
number of platelets from a baseline value of 286 ± 75 × 109/l to a maximum of 218 ± 83 × 109/l
with the nadir at 3 weeks. This study group found no evidence of either local or systemic
intolerance to treatment with 188Re-HEDP, while a flare reaction with an increase in pain within
14 days after therapy was noted in 16% of patients [75].
Biersack et al. [76] also showed the positive effect of repeated therapy on overall survival. They
retrospectively analyzed 60 hormone-refractory patients classified into three different groups
according to the number of therapies. Group A comprised patients who had received only one
therapy (19 patients), group B included patients who had received two therapies (19 patients),
and group C included patients who had received three or more therapies (22 patients). All
patients had bone pain and presented with more than five lesions documented by a bone scan.
Mean survival after the initial therapy improved from 4.5 months in group A to 9.98 months
in group B and 15.7 months in group C [76].
5.5. 153Samarium-EDTMP
153Sm-EDTMP has a lower β-emission energy [0.81 MeV (20%), 0.71 MeV (49%), and 0.64 MeV
(30%)], a 28% abundance of γ-emission at 103 keV (28%) and a physical half-life of 46.3 h.
153Sm forms a stable complex with ethylenediamine tetramethylene phosphonate (EDTMP).
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Clearance is bi-exponential after administration, comprising rapid bone uptake (half-life of 5.5
min) and plasma renal clearance (half-life of 65 min) [77].
A dose escalation study with 10–36 MBq/kg of 153Sm-EDTMP reported a pain relief rate of 65%,
with a duration range from 4 to 35 weeks [78]. A further dose escalation study in 52 patients
using administered activities from 37 to 111 MBq/kg had a response rate of 74% with a median
duration of 10 weeks [79]. Larger studies with more than 100 patients showed a median
therapeutic efficacy of 80%. In a randomized, double-blind, placebo trial (n = 152), pain relief
was found in 65% of patients after 153Sm-EDTMP treatment compared to 45% in the placebo
group [80]. A significant decrease in pain between 153Sm-EDTMP and placebo was reported
after 1 week, and the analgesic intake was significantly reduced after 3 and 4 weeks. Two large
studies using 153Sm-EDTMP with more than 550 patients reported response rates of 73 and 86%
[81, 82].
5.6. Comparing the pain response between different radionuclides
Dickie et al. compared 89Sr with 153Sm in 57 prostate cancer patients. They found no difference
in the pain response rate and toxicity [83]. van der Poel et al. compared 186Re with 89Sr and
reported no differences in the response rate or toxicity [54]. A nonrandomized comparison of
188Re-HEDP and 153Sm-EDTMP in patients with painful metastases from prostate and breast
cancer by Liepe et al. [84] showed a comparable response and toxicity with both agents. Liepe
et al. also performed a comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP, and
89SrCl2 in the treatment of painful bone metastases. They reported that all radiopharmaceuticals
were effective in pain palliation, without the induction of severe side effects or significant
differences in therapeutic efficacy or toxicity [39].
5.7. 223Radium dichloride
223Ra, an α-emitter, has a half-life of 11.4 days, with a total emitted energy of about 28 MeV. It
is the only FDA-approved radiopharmaceutical for the treatment of bone metastases of PC
with positive impact on overall survival according to a prospective randomized study [10]. It
is a bone stromal-targeted radiopharmaceutical that undergoes α-emission. The α-particle is
considerably more destructive to tumor cells than the β-particle. 223Ra has a very high linear
energy transfer, and only one to five hits per cell can be fatal. Double-strand breaks are induced
even in quiescent cells and at low oxygen levels [85].
The penetration range of α-particles (<100 μm) in tissue is much smaller than that of previously
described β-emitters in this chapter; so, despite the high energy, because of the short penetra‐
tion range, bone marrow damage is minimal [86]. Nonhematological toxicities are more
commonly observed, and are mild to moderate in intensity. The most common side effects are
diarrhea, fatigue, nausea, vomiting, and bone pain, some of which are dose-related [87–89].
These side effects are easily manageable with symptomatic and supportive treatments [90].
Parker et al. [89] performed a randomized, double-blind, dose-finding, Phase II study that
included 122 PC patients who were randomized to be treated with three injections of 223Ra at
6-week intervals, at doses of 25 kBq/kg (n = 41), 50 kBq/kg (n = 39), or 80 kBq/kg (n = 42). They
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compared the proportion of patients in each group with confirmed PSA decline of ≥50%. No
patient in the 25 kBq/kg dose group showed a significant PSA decline ≥50%. In the 50 kBq/kg
dose group, only two patients (6%) showed a significant PSA decline, whereas in five patients
(13%) in the 80 kBq/kg dose group, a significant PSA decline was reported (P = 0.0297). A ≥50%
decrease in the bone alkaline phosphatase level was reported in 6 patients (16%), 24 patients
(67%), and 25 patients (66%), in the 25, 50, and 80 kBq/kg dose groups, respectively (P < 0.0001).
The most common treatment-related adverse events (≥10%) occurring up to week 24 across all
dose groups were diarrhea (21%), nausea (16%), and anemia (14%). No difference in the
incidence of hematological events was seen among the dose groups. They concluded that 223Ra
had a dose-dependent effect on serum markers of PC activity, suggesting that controlling bone
disease with 223Ra may affect cancer-related outcomes [89].
The ALSYMPCA trial (ALpharadin in SYMptomatic Prostate CAncer) is the first randomized
Phase III study demonstrating improved survival with a bone-seeking radioisotope [42]. The
number of PC patients recruited was 921. All patients were required to have progressed with
symptomatic bone metastases, with at least two or more metastases on bone scintigraphy with
no known visceral metastases. Randomization was 2:1 in a double-blind fashion to receive six
cycles of intravenous 223Ra every 4 weeks with best standard of care or six infusions of placebo
with best standard of care. This study demonstrated a significant prolongation of survival (14.9
vs. 11.3 months, respectively; P < 0.001). Apart from this, the frequency of skeletal-related
events was reduced in the 223Ra group, and the median time to a skeletal-related event increased
(15.6 vs. 9.8 months; P < 0.001). 223Ra was well-tolerated with low rates of grade 3/4 neutropenia
(1.8 vs. 0.8%) and thrombocytopenia (4 vs. 2%) [42].
Etchebehere et al. retrospectively reviewed 110 patients with metastatic PC treated with 223Ra.
The end points of this study were overall survival, bone event-free survival, progression-free
survival (PFS), and bone marrow failure. They evaluated the following parameters prior to the
first therapy cycle: hemoglobin (Hb), PSA, alkaline phosphatase (ALP), ECOG status, pain
score, prior chemotherapy, and external beam radiation therapy (EBRT). Furthermore during/
after 223Ra, the PSA doubling time (PSADT), the total number of radium cycles (RaTot), and
the use of chemotherapy, EBRT, enzalutamide, and abiraterone were evaluated. A significant
reduction of alkaline phosphatase and pain score occurred throughout the 223Ra cycles. The
risk of progression was associated with declining ECOG status and decrease in PSADT. RaTot,
initial ECOG(Eastern Cooperative Oncology Group) status, ALP, initial pain score, and the
use of abiraterone were associated with OS (P ≤ 0.008), PFS (P ≤ 0.003), and BeFS (P ≤ 0.020).
RaTot, initial ECOG status, ALP, and initial pain score were significantly associated with bone
marrow failure (P ≤ 0.001), as well as Hb (P < 0.001) and EBRT (P = 0.009). In the multivariable
analysis, only RaTot and abiraterone remained significantly associated with OS (P < 0.001 and
P = 0.033, respectively), PFS (P < 0.001 and P = 0.041, respectively), and BeFS (P < 0.001 and P
= 0.019, respectively). Additionally, RaTot (P = 0.027) and EBRT (P = 0.013) remained signifi‐
cantly associated with bone marrow failure. They concluded that the concomitant use of
abiraterone and 223Ra seems to have a beneficial effect, while EBRT may increase the risk of
bone marrow failure [91].
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Recently, Pacilio et al. [90] performed a dosimetry study and showed that the lesion uptake of
223Ra was significantly correlated with that of 99mTc-MDP. The DRBE (RBE, relative biological
effectiveness; DRBE, RBE-weighted absorbed dose) to lesions per unit administered activity was
much higher than that of other bone-seeking radiopharmaceuticals, but considering a standard
administration of 21 MBq (six injections of 50 kBq/kg to a 70-kg patient), the mean cumulative
value of DRBE was about 19 Gy, and was therefore in a similar range as other radiopharma‐
ceuticals.
Nilsson et al. [92] reported the quality-of-life results of the ALSYMPCA study. It was found
that improved survival with 223Ra was accompanied by significant quality-of-life benefits,
including a higher percentage of patients with meaningful quality-of-life improvements and
a slower decline in quality-of-life over time.
6. Conclusion
A pain response is seen in approximately one-half of patients treated with radionuclides for
painful osseous metastases of prostate cancer. The ALSYMPCA study showed an OS benefit
with 223Ra treatment. However, it should be mentioned that this study was supported by the
company, Bayer. The other radiopharmaceuticals which are mentioned in this chapter were
not tested in prospective multicenter trials with a large number of patients. This means that
β-emitters could also have an OS benefit, which was shown in only a few studies. A combi‐
nation of hormone therapy with bone-targeted therapy may be more effective than a single
therapy approach. Different combinations of therapies are being studied at the moment.
PSMA-targeted therapy has so far shown very promising results. According to the published
studies, 177Lu-PSMA therapy after 223Ra is feasible and safe.
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